Short Interest in Quantum Biopharma Ltd. (NASDAQ:QNTM) Rises By 63.2%

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 76,665 shares, an increase of 63.2% from the January 15th total of 46,986 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average trading volume of 65,698 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 65,698 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.2% of the shares of the stock are sold short.

Quantum Biopharma Price Performance

Shares of QNTM opened at $3.64 on Friday. Quantum Biopharma has a 1 year low of $3.62 and a 1 year high of $38.25. The stock has a 50 day simple moving average of $6.88 and a two-hundred day simple moving average of $12.41. The firm has a market cap of $13.89 million, a P/E ratio of -0.33 and a beta of 0.30.

Analysts Set New Price Targets

QNTM has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC purchased a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned 0.29% of Quantum Biopharma as of its most recent SEC filing. 1.24% of the stock is owned by hedge funds and other institutional investors.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.